VELAVIGO
Li Jing
Application Filed: 2021-07-20
Trademark Application Details
NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
| Research |
OneLook
Acronym Finder
|
| Serial Number | 90838630 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Attorney Name | Kathryn E. Smith |
| Attorney Docket Number | JING02128 |
Timeline
| 2021-07-20 | Application Filed |
| 2021-07-23 | Location: NEW APPLICATION PROCESSING |
| 2021-07-23 | Status: Live/Pending |
| 2021-07-23 | Transaction Date |
Trademark Applicants & Owners
| Owner: |  Li Jing |
| Address | 11 Dunham Street Lexington MA US 02420 |
| Legal Entity Type | Individual |
| Legal Entity State | US |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 005,006,018,044,046,051,052 |
| International Codes: | 35 |
| U.S. Codes: | 100,101,102 |
| International Codes: | 42 |
| U.S. Codes: | 100,101 |
| International Codes: | 44 |
| U.S. Codes: | 100,101 |
| Type Code | Type |
|---|---|
| GS0051 | Chemical preparations for medical purposes; bulk drugs; biochemical medicines; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; medicines for human purposes; pharmaceutical preparations; chemico-pharmaceutical preparations; drugs for medical purposes; biological preparations for medical purposes; chemical preparations for pharmaceutical purposes; radioactive substances for medical purposes; gases for medical purposes; chemical conductors for electrocardiograph electrodes; semen for artificial insemination; disinfectants; solutions for contact lenses; media for bacteriological cultures; medicated sweets; dietetic substances adapted for medical use; depuratives; veterinary preparations; pesticides; sanitary napkins; cotton for medical purposes; dental abrasives; diapers for pets |
| GS0051 | Chemical preparations for medical purposes used for treating tumors, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, cancer, autoimmune diseases, inflammation and antivirals; bulk drugs in the nature of pharmaceutical preparations, namely, for treating tumors, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, cancer, autoimmune diseases, inflammation and antivirals; diagnostic preparations for medical purposes; biochemical medicines, namely, for use in treating tumors, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, cancer, autoimmune diseases, inflammation and antivirals; diagnostic biomarker reagents for medical purposes; medicines for human purposes used for treating tumors, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, cancer, autoimmune diseases, inflammation and antivirals; pharmaceutical preparations used for treating tumors, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, cancer, autoimmune diseases, inflammation and antivirals; chemico-pharmaceutical preparations used for treating tumors, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, cancer, autoimmune diseases, inflammation and antivirals; drugs in the nature of pharmaceutical preparations for medical purposes used for treating tumors, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, cancer, autoimmune diseases, inflammation and antivirals; biological preparations for medical purposes used for treating tumors, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, autoimmune diseases, inflammation, cancer, and antivirals; chemical preparations for pharmaceutical purposes used for treating tumors, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, autoimmune diseases, inflammation, cancer, and antivirals; radioactive substances for medical purposes; gases for medical purposes; chemical conductors for electrocardiograph electrodes; semen for artificial insemination; disinfectants; solutions for contact lenses; media for bacteriological cultures; medicated sweets; dietetic foods and beverages adapted for medical use; depuratives for the body; pesticides; sanitary napkins; cotton for medical purposes; dental abrasives; diapers for pets |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| NEW APPLICATION ENTERED IN TRAM | 2021-07-23 | 1 NWAP I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2021-09-21 | 2 NWOS I:Incoming Correspondence |
| TEAS VOLUNTARY AMENDMENT RECEIVED | 2021-08-17 | 3 PARI I:Incoming Correspondence |
| ASSIGNED TO LIE | 2021-10-04 | 4 ALIE A:Allowance for Publication |
| PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | 2021-10-05 | 5 AMPX O:Outgoing Correspondence |
| ASSIGNED TO EXAMINER | 2022-04-12 | 6 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2022-04-21 | 7 CNRT R:Renewal |
| NON-FINAL ACTION E-MAILED | 2022-04-21 | 8 GNRT F:First Action |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2022-04-21 | 9 GNRN O:Outgoing Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2022-10-20 | 10 TROA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2022-10-20 | 11 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2022-10-20 | 12 TEME I:Incoming Correspondence |
| SUSPENSION LETTER WRITTEN | 2022-10-24 | 13 CNSL R:Renewal |
| LETTER OF SUSPENSION E-MAILED | 2022-10-24 | 14 GNSL S: |
| NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | 2022-10-24 | 15 GNS3 O:Outgoing Correspondence |
| ASSIGNED TO EXAMINER | 2022-11-23 | 16 DOCK D:Assigned to Examiner |
| SUSPENSION CHECKED ¿ TO ATTORNEY FOR ACTION | 2023-04-26 | 17 RCCK S: |
| AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | 2023-05-03 | 18 ASGN I:Incoming Correspondence |
| SUSPENSION CHECKED ¿ TO ATTORNEY FOR ACTION | 2023-05-09 | 19 RCCK S: |
| TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | 2023-05-11 | 20 ERSI I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2023-05-12 | 21 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2023-05-12 | 22 TEME I:Incoming Correspondence |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2023-05-15 | 23 CNSA O:Outgoing Correspondence |
| LAW OFFICE PUBLICATION REVIEW COMPLETED | 2023-05-23 | 24 PREV O:Outgoing Correspondence |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2023-06-07 | 25 NONP E:E-Mail |
| PUBLISHED FOR OPPOSITION | 2023-06-27 | 26 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2023-06-27 | 27 NPUB E:E-Mail |
| EXTENSION OF TIME TO OPPOSE RECEIVED | 2023-07-24 | 28 ETOF T:TTAB Proceeding |
| EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | 2023-11-05 | 29 ETOP T:TTAB Proceeding |
| REGISTERED-PRINCIPAL REGISTER | 2023-12-12 | 30 R.PR A:Allowance for Publication |
| NOTICE OF REGISTRATION CONFIRMATION EMAILED | 2023-12-12 | 31 NRCC E:E-Mail |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 